Having a beer!!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GTHR - Covid-19 * Read, Read, Read... This could be huge!
https://www.otcmarkets.com/filing/html?id=14210924&guid=xqkFU6XpGG8XM3h
Business Model
Molecular Robotic Artificial Intelligence (AI) Integrated Platform (MORAP)
It has become evident from the COVID-19 global pandemic that current systems and related technologies are not capable of preventing or successfully controlling the spreads of zoonotic infectious agents. One of the features of these infectious organisms is their ability to infect both people and animals while some carriers remain asymptomatic for a period of time or for the entire duration of the infection. We believe it is imperative that during pandemic outbreaks the entire population must be tested for the presence of infection agents. In addition, we believe that AI models should be developed to analyze data and forecast zoonotic diseases outbreak and ultimately prevent epidemics and pandemics from occurring in the future. GeneThera’s goal is to develop the infrastructure of a nationwide zoonotic infectious agents “alert shield” which would operate to predict, detect and manage the spread of pandemics and ultimately prevent pandemics from developing, similar to a “nuclear shield,” which is designed to detect incoming nuclear warheads and destroy them before they can be deployed. We believe that a nationwide network of AI controlled laboratory robotic systems may be able to perform such a task.
Our business model is based on an Ultra High Throughput Molecular Robotic/AI Platform (MORAP) which combines the use of advance robotic integrated systems with AI and Machine Learning (ML) software systems. Upon development, MORAP would encompass a nationwide network of interactive molecular laboratories operated using advanced integrated robotic and machine learning cloud-based software systems, which would be able to share data and interact with each other. We believe the MORAP would be capable of processing millions of samples and collecting, storing and analyzing data. We believe that the MORAP nationwide communications network could be accomplished through advanced cloud-based software systems, machine learning and Internet-of-Things (IoT) networks. MORAP could be readily replicated and scaled utilizing identical instrumentation and software.
We have designed the MORAP’s second generation molecular robotic/AI laboratory system prototype. Upon development subject to securing the requisite funding, each individual MORAP system would be capable, in a full-scale commercial platform, to perform over 100,000 samples/daily with minimal human intervention.
We envision the MORAP’s cloud-based AI-integrated software system with a dual purpose: 1) data obtained from each individual robotic laboratory system would be sent to the cloud to be stored where data could be analyzed and risk factors could be evaluated; and 2) each individual robotic laboratory system as part of the MORAP network could be configured in the cloud. The individual robotic laboratory systems, identical in each location, would be controlled and operated through MORAP’s cloud-based software.
The MORAP’s cloud software architecture would:
1)Collect and analyze data from each run performed by each robotic clone;
2)Compare data between runs from individual robotic clones and determined risk factors;
3)Send commands to operate each robotic clone; and
4)Run diagnostics for each clone and alert and possibly fix any software or hardware problem the system may experience.
Each individual robotic unit is composed of different equipment controlled by the integrated software. The MORAP cloud-base system would be function as the ‘brain’ of the entire network.
Our MORAP system is designed to targeted zoonotic diseases in general; however, we intend to focus our robotic/AI and therapeutic vaccine technologies on SARS-Cov-2 and MAP related diseases.
Zoonotic Diseases Vaccine Development
Our therapeutic vaccine technology is based on the use of CRISPR gene editing technology. CRISPR technology is a new technique that is based on the use of short RNA sequences complementary to a specific target gene. Once the RNA sequence binds to the gene, the gene is deactivated or “silenced” and no longer able to produce the specific protein. It also allows for the efficient, effective, and continuous testing, management and treatment of animal populations. We plan to deliver CRISPR modified RNA sequences motif using our proprietary PURIVAX technology. Our focus will be to develop CRISPR based vaccines for SARS-COV-2 and MAP. Our strategy is to silence the expression of gene pathways, which are activated by the infectious agents to gain entry into the host cells.
***GTHR - Covid-19 Read, Read, Read... 10-K dropped after-hours on the OTC website. This could be huge!***
https://www.otcmarkets.com/filing/html?id=14210924&guid=xqkFU6XpGG8XM3h
Business Model
Molecular Robotic Artificial Intelligence (AI) Integrated Platform (MORAP)
It has become evident from the COVID-19 global pandemic that current systems and related technologies are not capable of preventing or successfully controlling the spreads of zoonotic infectious agents. One of the features of these infectious organisms is their ability to infect both people and animals while some carriers remain asymptomatic for a period of time or for the entire duration of the infection. We believe it is imperative that during pandemic outbreaks the entire population must be tested for the presence of infection agents. In addition, we believe that AI models should be developed to analyze data and forecast zoonotic diseases outbreak and ultimately prevent epidemics and pandemics from occurring in the future. GeneThera’s goal is to develop the infrastructure of a nationwide zoonotic infectious agents “alert shield” which would operate to predict, detect and manage the spread of pandemics and ultimately prevent pandemics from developing, similar to a “nuclear shield,” which is designed to detect incoming nuclear warheads and destroy them before they can be deployed. We believe that a nationwide network of AI controlled laboratory robotic systems may be able to perform such a task.
Our business model is based on an Ultra High Throughput Molecular Robotic/AI Platform (MORAP) which combines the use of advance robotic integrated systems with AI and Machine Learning (ML) software systems. Upon development, MORAP would encompass a nationwide network of interactive molecular laboratories operated using advanced integrated robotic and machine learning cloud-based software systems, which would be able to share data and interact with each other. We believe the MORAP would be capable of processing millions of samples and collecting, storing and analyzing data. We believe that the MORAP nationwide communications network could be accomplished through advanced cloud-based software systems, machine learning and Internet-of-Things (IoT) networks. MORAP could be readily replicated and scaled utilizing identical instrumentation and software.
We have designed the MORAP’s second generation molecular robotic/AI laboratory system prototype. Upon development subject to securing the requisite funding, each individual MORAP system would be capable, in a full-scale commercial platform, to perform over 100,000 samples/daily with minimal human intervention.
We envision the MORAP’s cloud-based AI-integrated software system with a dual purpose: 1) data obtained from each individual robotic laboratory system would be sent to the cloud to be stored where data could be analyzed and risk factors could be evaluated; and 2) each individual robotic laboratory system as part of the MORAP network could be configured in the cloud. The individual robotic laboratory systems, identical in each location, would be controlled and operated through MORAP’s cloud-based software.
The MORAP’s cloud software architecture would:
1)Collect and analyze data from each run performed by each robotic clone;
2)Compare data between runs from individual robotic clones and determined risk factors;
3)Send commands to operate each robotic clone; and
4)Run diagnostics for each clone and alert and possibly fix any software or hardware problem the system may experience.
Each individual robotic unit is composed of different equipment controlled by the integrated software. The MORAP cloud-base system would be function as the ‘brain’ of the entire network.
Our MORAP system is designed to targeted zoonotic diseases in general; however, we intend to focus our robotic/AI and therapeutic vaccine technologies on SARS-Cov-2 and MAP related diseases.
Zoonotic Diseases Vaccine Development
Our therapeutic vaccine technology is based on the use of CRISPR gene editing technology. CRISPR technology is a new technique that is based on the use of short RNA sequences complementary to a specific target gene. Once the RNA sequence binds to the gene, the gene is deactivated or “silenced” and no longer able to produce the specific protein. It also allows for the efficient, effective, and continuous testing, management and treatment of animal populations. We plan to deliver CRISPR modified RNA sequences motif using our proprietary PURIVAX technology. Our focus will be to develop CRISPR based vaccines for SARS-COV-2 and MAP. Our strategy is to silence the expression of gene pathways, which are activated by the infectious agents to gain entry into the host cells.
Where are you Gary? You see the filing!
GTHR - Covid-19 * Read, Read, Read... This could be huge!
https://www.otcmarkets.com/filing/html?id=14210924&guid=xqkFU6XpGG8XM3h
Business Model
Molecular Robotic Artificial Intelligence (AI) Integrated Platform (MORAP)
It has become evident from the COVID-19 global pandemic that current systems and related technologies are not capable of preventing or successfully controlling the spreads of zoonotic infectious agents. One of the features of these infectious organisms is their ability to infect both people and animals while some carriers remain asymptomatic for a period of time or for the entire duration of the infection. We believe it is imperative that during pandemic outbreaks the entire population must be tested for the presence of infection agents. In addition, we believe that AI models should be developed to analyze data and forecast zoonotic diseases outbreak and ultimately prevent epidemics and pandemics from occurring in the future. GeneThera’s goal is to develop the infrastructure of a nationwide zoonotic infectious agents “alert shield” which would operate to predict, detect and manage the spread of pandemics and ultimately prevent pandemics from developing, similar to a “nuclear shield,” which is designed to detect incoming nuclear warheads and destroy them before they can be deployed. We believe that a nationwide network of AI controlled laboratory robotic systems may be able to perform such a task.
Our business model is based on an Ultra High Throughput Molecular Robotic/AI Platform (MORAP) which combines the use of advance robotic integrated systems with AI and Machine Learning (ML) software systems. Upon development, MORAP would encompass a nationwide network of interactive molecular laboratories operated using advanced integrated robotic and machine learning cloud-based software systems, which would be able to share data and interact with each other. We believe the MORAP would be capable of processing millions of samples and collecting, storing and analyzing data. We believe that the MORAP nationwide communications network could be accomplished through advanced cloud-based software systems, machine learning and Internet-of-Things (IoT) networks. MORAP could be readily replicated and scaled utilizing identical instrumentation and software.
We have designed the MORAP’s second generation molecular robotic/AI laboratory system prototype. Upon development subject to securing the requisite funding, each individual MORAP system would be capable, in a full-scale commercial platform, to perform over 100,000 samples/daily with minimal human intervention.
We envision the MORAP’s cloud-based AI-integrated software system with a dual purpose: 1) data obtained from each individual robotic laboratory system would be sent to the cloud to be stored where data could be analyzed and risk factors could be evaluated; and 2) each individual robotic laboratory system as part of the MORAP network could be configured in the cloud. The individual robotic laboratory systems, identical in each location, would be controlled and operated through MORAP’s cloud-based software.
The MORAP’s cloud software architecture would:
1)Collect and analyze data from each run performed by each robotic clone;
2)Compare data between runs from individual robotic clones and determined risk factors;
3)Send commands to operate each robotic clone; and
4)Run diagnostics for each clone and alert and possibly fix any software or hardware problem the system may experience.
Each individual robotic unit is composed of different equipment controlled by the integrated software. The MORAP cloud-base system would be function as the ‘brain’ of the entire network.
Our MORAP system is designed to targeted zoonotic diseases in general; however, we intend to focus our robotic/AI and therapeutic vaccine technologies on SARS-Cov-2 and MAP related diseases.
Zoonotic Diseases Vaccine Development
Our therapeutic vaccine technology is based on the use of CRISPR gene editing technology. CRISPR technology is a new technique that is based on the use of short RNA sequences complementary to a specific target gene. Once the RNA sequence binds to the gene, the gene is deactivated or “silenced” and no longer able to produce the specific protein. It also allows for the efficient, effective, and continuous testing, management and treatment of animal populations. We plan to deliver CRISPR modified RNA sequences motif using our proprietary PURIVAX technology. Our focus will be to develop CRISPR based vaccines for SARS-COV-2 and MAP. Our strategy is to silence the expression of gene pathways, which are activated by the infectious agents to gain entry into the host cells.
GTHR - Covid-19 * Read, Read, Read... This could be huge!
https://www.otcmarkets.com/filing/html?id=14210924&guid=xqkFU6XpGG8XM3h
Business Model
Molecular Robotic Artificial Intelligence (AI) Integrated Platform (MORAP)
It has become evident from the COVID-19 global pandemic that current systems and related technologies are not capable of preventing or successfully controlling the spreads of zoonotic infectious agents. One of the features of these infectious organisms is their ability to infect both people and animals while some carriers remain asymptomatic for a period of time or for the entire duration of the infection. We believe it is imperative that during pandemic outbreaks the entire population must be tested for the presence of infection agents. In addition, we believe that AI models should be developed to analyze data and forecast zoonotic diseases outbreak and ultimately prevent epidemics and pandemics from occurring in the future. GeneThera’s goal is to develop the infrastructure of a nationwide zoonotic infectious agents “alert shield” which would operate to predict, detect and manage the spread of pandemics and ultimately prevent pandemics from developing, similar to a “nuclear shield,” which is designed to detect incoming nuclear warheads and destroy them before they can be deployed. We believe that a nationwide network of AI controlled laboratory robotic systems may be able to perform such a task.
Our business model is based on an Ultra High Throughput Molecular Robotic/AI Platform (MORAP) which combines the use of advance robotic integrated systems with AI and Machine Learning (ML) software systems. Upon development, MORAP would encompass a nationwide network of interactive molecular laboratories operated using advanced integrated robotic and machine learning cloud-based software systems, which would be able to share data and interact with each other. We believe the MORAP would be capable of processing millions of samples and collecting, storing and analyzing data. We believe that the MORAP nationwide communications network could be accomplished through advanced cloud-based software systems, machine learning and Internet-of-Things (IoT) networks. MORAP could be readily replicated and scaled utilizing identical instrumentation and software.
We have designed the MORAP’s second generation molecular robotic/AI laboratory system prototype. Upon development subject to securing the requisite funding, each individual MORAP system would be capable, in a full-scale commercial platform, to perform over 100,000 samples/daily with minimal human intervention.
We envision the MORAP’s cloud-based AI-integrated software system with a dual purpose: 1) data obtained from each individual robotic laboratory system would be sent to the cloud to be stored where data could be analyzed and risk factors could be evaluated; and 2) each individual robotic laboratory system as part of the MORAP network could be configured in the cloud. The individual robotic laboratory systems, identical in each location, would be controlled and operated through MORAP’s cloud-based software.
The MORAP’s cloud software architecture would:
1)Collect and analyze data from each run performed by each robotic clone;
2)Compare data between runs from individual robotic clones and determined risk factors;
3)Send commands to operate each robotic clone; and
4)Run diagnostics for each clone and alert and possibly fix any software or hardware problem the system may experience.
Each individual robotic unit is composed of different equipment controlled by the integrated software. The MORAP cloud-base system would be function as the ‘brain’ of the entire network.
Our MORAP system is designed to targeted zoonotic diseases in general; however, we intend to focus our robotic/AI and therapeutic vaccine technologies on SARS-Cov-2 and MAP related diseases.
Zoonotic Diseases Vaccine Development
Our therapeutic vaccine technology is based on the use of CRISPR gene editing technology. CRISPR technology is a new technique that is based on the use of short RNA sequences complementary to a specific target gene. Once the RNA sequence binds to the gene, the gene is deactivated or “silenced” and no longer able to produce the specific protein. It also allows for the efficient, effective, and continuous testing, management and treatment of animal populations. We plan to deliver CRISPR modified RNA sequences motif using our proprietary PURIVAX technology. Our focus will be to develop CRISPR based vaccines for SARS-COV-2 and MAP. Our strategy is to silence the expression of gene pathways, which are activated by the infectious agents to gain entry into the host cells.
They slipped those filings in. Having came through the OTC website yet. Should be a runner tomorrow for sure.
GTHR Covid-19 stock filings just hit.
COVID-19
COVID-19 is an infectious disease caused by SARS- CoV-2. Common symptoms include fever, cough and shortness of breath. Other symptoms may include muscle pain, diarrhea, sore throat, and loss of smell. The majority of cases result in mild symptoms. However, some cases progress to viral pneumonia and multi-organ failure. SARS-Cov-2 coronavirus is the latest example of a long list of viruses and bacteria that can cause widespread global infection in humans. As of early June 10, 2020, the number of infectious cases worldwide were close to seven and a half million with more than 415,000 deaths. In December 2019, SARS- Cov-2 was first discovered in the city of Wuhan, China. In February 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic. The SARS-Cov-2 is a genetically mutated strain of the SARS-Cov-1 virus that caused SARS in 2003-2004 epidemic. Coronaviruses are opportunistic viruses that are harbor in the Asian bat population. Pangolins, nocturnal mammals, native to Asia and Africa especially tropical forests, are the most likely intermediate carriers of the SARS-Cov-2 between bats and humans. In 2002–03, Civet cats, nocturnal mammals found in Asia and Africa sold for meat in local markets of China’s Yunnan province carried the SARS virus from bats to humans.
SARS-CoV-1 and 2’s abilities to genetically mutate through passages into humans is one of the reasons of their enhanced virulence. Coronaviruses are easily transmitted by human-to-human close contact primarily through saliva droplets. Coronaviruses are “positive single stranded (ss) RNA virus. These types of viruses can replicate into human cells without using the host DNA as a template. Positive single stranded RNA viruses have genetic material that can function both as genome and messenger RNA. This feature allows the Coronaviruses to work more efficiently once it infects its target. SARS-Cov-2 is the etiological cause of COVID-19, a highly infectious respiratory disease causing an atypical pneumonia.
4
The mechanism of infections to humans is through saliva droplets caused by persistent cough and sneezing. Indirect contact with contaminated surfaces is another way of infection although it is not a very efficient way of transmission. Viral RNA is also being found in the stools of infected patients. SARS-Cov-2 is able to enter human cells by binding to the ACE2 cell receptor. Once inside the cells, the virus starts the process of replication by using its own RNA polymerase enzyme. The incubation time COVID-19 varies between 2-14 days. It is not clear if during the incubation period, the virus is able to infect humans.
Major clinical symptoms and epidemiological risk factors related to COVID-19:
?High Fever (>101)
?Persistent Cough
?Sneeze
?Dyspnea (severe cases)
?Pneumonia (severe cases)
?Fatigue
?Muscle pain
?Sore throat
?Organ failure (terminal cases)
?Higher mortality rate compared to influenza (>0.1-1%)
?Pre-existing medical conditions (cancer, cardiovascular diseases, diabetes, immunodeficiency diseases)
?Mortality Age factor (individuals >65yrs old)
?Saliva droplets transmission
?Aerosol transmission
?Virus can survive in the air up to 3 hours and on surfaces up to 72 hours
?Unknown asymptomatic transmission
?Global pandemic
Epidemiological evidences support the hypothesis that SARS-CoV-2 neuronal cells in the medulla oblongata region of the brain could become infected with the virus. Anosmia (loss of smell) and ageusia (loss of taste) are reported to be early signs of COVID-19. In some cases the neuronal infection of the medulla oblongata can contribute to a patient’s breathing problems and respiratory failure within five days from the infection. SARS-CoV-2 enters human cell by binding the ACE2 receptor. The ACE2 protein regulates cardiovascular function and is express in many human cells including lung, heart, kidney, intestine, and brain tissue. There are multiple ways the virus could invade the central nervous system. A possible mechanism of action is that the SARS-CoV-2 is in the blood of infected patients and through this infectious route binds to ACE2 receptors in the endothelial cells of the blood capillaries in the brain, breaching the blood-brain barrier and invading neurons through that route. A breached blood-brain barrier could also cause brain swelling, compressing the brain stem and affecting respiration. The cells innervating the lungs could also become infected, making involuntary respiration more difficult.
Evidence from experiments in mice also suggest that the virus might target the nervous system through the olfactory bulb. A study published in 2008 (Netland et al. J Virology 2008 Aug (15): 7264-7275) showed that SARS-CoV-1 — the virus that caused the SARS outbreak in 2003 — entered the brains of transgenic mice expressing human ACE2 through neurons in the nose. The virus then rapidly spread to connecting nerve cells. The extensive nerve damage was the major cause of death, even though, low levels of the virus were detected in the animals’ lungs. It is therefore possible that the respiratory failure in patients with COVID-19 could be caused from the extensive neuronal damages in the cardiorespiratory area of the medulla oblongata.
Diagnostics assays and Treatment of COVID -19
Nasopharyngeal, oropharyngeal swabs and saliva specimen are collected from patients to detect the SARS-Cov-2 viral infection. Viral RNA is extracted from the swab and amplified using the Real Time Polymerase Chain reaction (RT-PCR) technology. The COVID-19 detection molecular assay is a multi-step procedure that requires up to 72 hours to obtain a result. Because of the complexity of the assay, a limited number of samples can be manually processed daily. Limitations in the number of samples to be process is the main reason of the spreading of the COVID-19. Automated systems such as the Roche COBA 8800 are capable of processing up to 4,000 samples/daily. However, due to the sheer number of potentially infected people globally, this system could not fully meet assay demand.
Currently, no treatment is available to treat COVID-19. Influenza vaccines are not effective to stop the spread of COVID-19 infection. Several COVID-19 vaccines are currently in Phase I clinical trials. Estimated development time is between 15-18 months. Alternatively, “off label” drug combination protocols have been used, with various degree of success, to treat COVID-19 patients.
Looks like filings just hit. Haven't had time to go through them.
$ORVRF everyone missed the news yesterday. Going to be a big one imo.
https://finance.yahoo.com/news/orchid-ventures-announces-ecommerce-launch-103000220.html
IRVINE, CA / ACCESSWIRE / June 9, 2020 / ORCHID VENTURES, INC. (ORCD.CN) (OTC PINK:ORVRF) (the "Company" or "Orchid"), a multi-state cannabis innovation company is pleased to announce it has partnered with Driven (OTCQB:DRVD) to launch Orchid on their new ecommerce platform, Brand Budee. Driven is California's fastest growing online cannabis retailer and direct-to-consumer logistics company and its new ecommerce platform Brand Budee, allows Orchid customers to purchase directly from the Orchid website for delivery throughout the state of California.
"We are excited to be partnering with Driven on the new Brand Budee platform. We have already integrated it into our website and customers are now able to purchase products for delivery throughout the largest cannabis market in the country. Driven's other delivery service, GanjaRunner, has been one of Orchid's larger retail accounts for over a year and lately we have seen a significant increase in sales through their platform." said Corey Mangold, Founder & CEO. "We feel that this partnership will allow for more access to Orchid products as we continue to expand the licensing of the Orchid Essentials brand. It's a win for us, our licensees, and Driven."
"Driven and it's retail businesses, Ganjarunner and Budee, have had a long standing fruitful partnership with Orchid Essentials. The reputation and quality that accompanies Orchid's dedication to its customers is admired and shared by Driven," said Christian Schenk, CEO Driven Deliveries Inc. "We have seen great success together servicing California's consumers as a leading online retail partner and we look forward to accelerated momentum and continued competitive separation for both parties as a result of the implementation of the Brand Budee Widget on Orchid's website"
Orchid announces that the Board of Directors has approved a stock option grant, effective Monday June 1, 2020, for an aggregate of 7.9 million stock options (each, an "Option") to certain directors and officers of the Company in accordance with the Company's Stock Option Performance Plan. Each Option is exercisable into one common share in the capital of the Company at a price of $0.03 per share, being the closing price of the shares on the CSE on June 1, 2020, for a period of five years from the date of grant.
Story continues
https://orchidessentials.com/
https://m.facebook.com/orchidessentials/
6.4 million float
https://www.otcmarkets.com/stock/ORVRF/security
CELLg8® patented technology
https://www.google.com/amp/s/sports.yahoo.com/amphtml/orchid-ventures-announces-publishing-cbd-103000556.html
$BNCM reverse merger with 24/7labs. Covid-19 testing.
https://www.google.com/search?client=ms-android-verizon&sxsrf=ALeKk02JtX7qDh7EHu6IZG5TfVNkD2WN9Q%3A1591807799752&ei=Nw_hXsmeLYCMwbkPnLed2A0&q=24-7+labs+tampa&oq=24-7+labs+tampa&gs_lcp=ChNtb2JpbGUtZ3dzLXdpei1zZXJwEAMyBAgjECcyBAgjECcyBggAEBYQHjIGCAAQFhAeMgUIIRCgATIFCCEQoAE6BwgjEOoCECc6BQgAEJECOgUILhCDAToFCC4QsQM6BQgAEIMBOgIIADoFCAAQsQM6BAgAEEM6BAguEEM6CAgAELEDEJECOgIILjoHCAAQFBCHAjoHCCEQChCgAVDnMFihrgFgt7YBaAVwAHgAgAHQAogB1h6SAQcwLjcuOS4ymAEBoAEBsAEP&sclient=mobile-gws-wiz-serp#lkt=LocalPoiPosts&trex=m_t:lcl_akp,rc_f:nav,rc_ludocids:15406393585348671144,rc_q:24-7%2520Labs%2520Memorial%2520Hwy,ru_q:24-7%2520Labs%2520Memorial%2520Hwy,trex_id:nyxg9c
5 locations
Updated OTC Website
24-7 Labs is the first of a new line of innovative health care services. Our mission is to give people the power to control their health by providing convenient, affordable, and easy to understand options. We provide medical laboratory testing for Allergies, Pregnancy, Basic Wellness, Heart Health, Men & Women's Health, Hormones, Diabetes, Menopause, Thyroid issues and more. We are here for all your wellness testing needs, 24 hours a day, 7 days a week.
?
6107 Memorial Hwy
Suite F
Tampa, FL 33615
www.24-7labs.com813-932-3741anytimelab@24-7labs.com
SECURITY DETAILS
Market Cap ?
262,655
06/09/2020
Shares Out
931,399
05/29/2020
MORE
FINANCIAL REPORTING
Reporting Status
Dark: Alternative Reporting Standard
Audited Financials
Not Available
Latest Report
01/31/1993
CIK
0001384939
Fiscal Year End
12/31
COMPANY OFFICERS & CONTACTS
Marley Roldan
CEO
Dr. Larry Duran
President
Dr. Rey Linares
Chief Med. Officer
Dr. Jose Suarez
Ops. Supervisor
COMPANY DIRECTORS
Marley Roldan
Chairwoman, CEO
Dr. Larry Duran
Dr. Rey Linares
https://www.otcmarkets.com/stock/BNCM/profile
I'm definitely waiting. Will add on any pullbacks.
JTBK- HOD 251%. .10 coming soon.
JTBK- big bids coming in! Looking for that .10 push soon.
New Websites coming!
Check out their company!
https://mobile.twitter.com/IndicaCompany
https://www.jetblackcorp.com/
JTBK- up big. .0425. Small float. Cannabis products coming.
187% Going over .10. Check it out!
New Website coming!
https://www.jetblackcorp.com/
https://mobile.twitter.com/indicacompany
https://www.otcmarkets.com/stock/JTBK/news/Jetblack-Corp-OTC-JTBK-Discusses-Yield-Sign-and-Subsidiary-The-Indica-Company?id=263587
JTBK- moving back up 195%
Going over .10. Check it out!
https://mobile.twitter.com/indicacompany
https://www.otcmarkets.com/stock/JTBK/news/Jetblack-Corp-OTC-JTBK-Discusses-Yield-Sign-and-Subsidiary-The-Indica-Company?id=263587
$JTBK- going back up! .10s coming fast.
Website coming!
https://www.jetblackcorp.com/
https://mobile.twitter.com/jetblackcorp
Just staring too. Expecting some news soon with products coming! Big move coming imo.
$JTBK- up 100%. .10 coming fast.
Website coming!
https://www.jetblackcorp.com/
https://mobile.twitter.com/jetblackcorp
JTBK- 237%no shares down here. Big bids coming in.
JTBK- Goin guys! Up 170%
JTBK- Up 115% still going!
https://mobile.twitter.com/indicacompany
JTBK- up 129%. Something is up here. Super thin.
https://mobile.twitter.com/indicacompany
JTBK- up again today. 68% up! Small float.
https://mobile.twitter.com/indicacompany
JTBK- picked up a few shares here. Looks like filings coming and news on Twitter. Might be a good one.
https://mobile.twitter.com/indicacompany
I would say Desanti probably told them not to divulge to much information. I wouldn't hold my breath on that phone call lol. I'm really hoping you here back though. Lol.
Share price should start inching up as we get closer to the end of the month and anticipated filings imo. .10+ is looking doable!
Only one sell below .30 so far. Next leg is coming imo.
That's awesome. So that is great confirmation of what is going on man. Great news with the owner confirming what we have here! Big move coming soon!
Next leg up should come quickly imo. Hopefully we get to add more in the .20s and .30s if we are lucky. There were some asks in the .20s on Friday.
The reason I think this is important is Carlos seems to be the owner on documents filed with Florida. Definitely holds some weight here imo.
http://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults/OfficerRegisteredAgentName/Roldan%20carlos/Page1
https://m.facebook.com/story.php?story_fbid=10220257352655627&id=1582377122
Agreed. 250k market cap currently. I would think a 2 million market with merger would be fair. The covid testing should do that alone imo.
I'm jealous of you guys that got in below .20. the way this has traded the last couple days the float has to be about locked up imo. We could see some huge moves in points this week.
My buys alone moved this up pretty fast. Things should be interesting next week imo. I think it is safe to say we are at the ground floor with pps.
Clearly this one shouldn't be trading at these levels. Makes you wonder how many kits have been sold already! Each of those location probably do $250k+ in revenue yearly. This one going to be a big one imo.
I found an interesting Facebook post everyone should checkout. Those 247lab test must be hot!
https://m.facebook.com/story.php?story_fbid=10220257352655627&id=1582377122
Staley, I don't think you will be the only one. There was great information dug up over the weekend. I've a good feeling we test .50 tomorrow. A lot of new eyes here and the OTC website confirms a merger coming in with the new updated profile. Good luck bud.
Thanks for compiling that list. I'm sure I will be borrowing it come Monday.
Cheers